- MediciNova, Inc. has successfully **achieved enrollment** of the target number of participants in its **COMBAT-ALS Phase 2b/3 clinical trial**.  **[1226616_de39b83355da466eb9a85eaa3e4ed931_0]** 
- The trial is evaluating **MN-166 (ibudilast)** for the treatment of **Amyotrophic Lateral Sclerosis (ALS)**.  **[1226616_de39b83355da466eb9a85eaa3e4ed931_0]** 
- This milestone is considered a **significant step forward** in the development of MN-166, allowing the company to move into the next phase of the trial.  **[1226616_de39b83355da466eb9a85eaa3e4ed931_0]** 
- MN-166 is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, and is also in development for other neurodegenerative diseases such as progressive MS and DCM.  **[1226616_de39b83355da466eb9a85eaa3e4ed931_0]**

MEDICINOVA (MNOV)